SecBot SecBot
8-K ·Filed May 13, 2026

OMER

OMEROS CORP
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001437749-26-016718
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor YARTEMLEA prescription trends for Q2 and the EMA decision on TA-TMA approval expected mid-2026. NTAP final rule in August could further boost hospital demand.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.28
T+0 close · May 13, 2026 · via day close
Latest settled
+2.56%
T+60 · $13.62
Vs SPY
−1.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $13.28entry
  2. T+1 · 6mo ago 0.00%α −0.01% · $13.28
  3. T+5 · 6mo ago −9.94%α −9.22% · $11.96
  4. T+20 · 5mo ago −34.19%α −33.33% · $8.74
  5. T+60 · 3mo ago +2.56%α −1.03% · $13.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Omeros reported Q1 2026 results with first-ever YARTEMLEA commercial sales of $9.9M net, GAAP net income of $56.1M (vs a $33.5M loss a year ago), and non-GAAP adjusted net loss of $17.1M ($0.24/share) that beat consensus of -$0.28. Revenue slightly missed $10.1M consensus. CMS assigned a J-code effective July 1 and recommended NTAP, signaling improving reimbursement.

Key Financial Metrics

EPS
−$0.24
est −$0.28 · +14.3%
Revenue
$9.9M
est $10.1M · -2.0%
Rating
beat

Key Facts

  • First YARTEMLEA net sales of $9.9M in Q1 2026 (launched Jan 2026)
  • GAAP net income $56.1M vs net loss of $33.5M in Q1 2025
  • Non-GAAP adjusted net loss $17.1M ($0.24/share) beat consensus $-0.28
  • Revenue $9.9M vs consensus $10.1M (miss of ~2%)
  • CMS assigned permanent J-code for YARTEMLEA (effective July 1) and recommended NTAP
  • Cash and short-term investments $135.3M at March 31; only $70.8M debt remaining (2029 Notes)
  • Repurchased 0.4M shares for $4.2M during Q1

Financial Impact

First commercial YARTEMLEA sales of $9.9M; non-GAAP EPS beat consensus by 14%

revenueeps

Risk Factors

  • YARTEMLEA adoption may slow without broader label or EU approval
  • Non-GAAP adjusted operations still unprofitable; cash burn continues
  • Revenue miss could pressure near-term expectations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-016718
Document: omer20260403_8k.htm0001437749-26-016718
Document: 0001437749-26-016718-index-headers.html0001437749-26-016718
Document: 0001437749-26-016718-index.html0001437749-26-016718
Document: 0001437749-26-016718.txt0001437749-26-016718
8-K Data (Synthetic)0001437749-26-016718

Track record

12 reports on OMER

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +98.11% at T+60 after the Jul 20, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.92 Now $16.68 −1.42% settles Feb 4
  2. Oct 30, 202617d ago 8-K Neutral 3/10 Entry $17.83 Now $16.68 −6.45% settles Jan 29
  3. Sep 1, 202610w ago Insider Cluster Neutral 2/10 Entry $18.86 Now $16.68 −11.56% settles Nov 27
  4. Aug 28, 202611w ago Insider Cluster Neutral Not scored Entry $18.79 Now $16.68 −11.23% settles Nov 24
  5. Aug 25, 202611w ago Insider Cluster Neutral 3/10 Entry $18.22 Now $16.68 −8.45% settles Nov 19
  6. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $19.32 Now $16.68 −13.66% settles Nov 17
  7. Jul 20, 202617w ago 8-K Bullish 5/10 Entry $9.53 to $18.88 Now $16.68 +75.03% ▲ +98.11% +94.14% vs SPY
  8. Jul 6, 202619w ago 8-K Neutral 4/10 Entry $10.34 to $19.25 Now $16.68 +61.32% ▲ +86.17% +84.45% vs SPY
  9. Jun 18, 202621w ago 8-K Bullish 5/10 Entry $10.28 to $17.46 Now $16.68 +62.26% ▲ +69.84% +67.95% vs SPY
  10. Jun 11, 202622w ago Institutional Cluster Neutral 4/10 Entry $10.18 to $18.95 Now $16.68 +63.85% ▲ +86.15% +81.75% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026